Vis enkel innførsel

dc.contributor.authorPandhi, Paloma
dc.contributor.authorStreng, Koen W.
dc.contributor.authorAnker, Stefan D.
dc.contributor.authorCleland, John G.
dc.contributor.authorDamman, Kevin
dc.contributor.authorDickstein, Kenneth
dc.contributor.authorPellicori, Pierpaolo
dc.contributor.authorLang, Chim C.
dc.contributor.authorNg, Leong
dc.contributor.authorSamani, Nilesh J.
dc.contributor.authorZannad, Faiez
dc.contributor.authorMetra, Marco
dc.contributor.authorRossignol, Patrick
dc.contributor.authorFilippatos, Gerasimos
dc.contributor.authorvan Veldhuisen, Dirk J.
dc.contributor.authorVoors, Adriaan A.
dc.contributor.authorter Maaten, Jozine M.
dc.date.accessioned2022-04-21T08:09:29Z
dc.date.available2022-04-21T08:09:29Z
dc.date.created2022-01-12T12:33:27Z
dc.date.issued2021
dc.identifier.issn2190-5991
dc.identifier.urihttps://hdl.handle.net/11250/2991831
dc.description.abstractBackground Muscle wasting and unintentional weight loss (cachexia) have been associated with worse outcomes in heart failure (HF), but timely identification of these adverse phenomena is difficult. Spot urinary creatinine may be an easily accessible marker to assess muscle loss and cachexia. This study investigated the association of urinary creatinine with body composition changes and outcomes in patients with new-onset or worsening HF (WHF). Methods In BIOSTAT-CHF, baseline spot urinary creatinine measurements were available in 2315 patients with new-onset or WHF in an international cohort (index cohort) and a validation cohort of 1431 similar patients from Scotland. Results Median spot urinary creatinine concentrations were 5.2 [2.7–9.6] mmol/L in the index cohort. Median age was 69 ± 12 years and 73% were men. Lower spot urinary creatinine was associated with older age, lower height and weight, worse renal function, more severe HF, and a higher risk of >5% weight loss from baseline to 9 months (odds ratio = 1.23, 95% CI = 1.09–1.39 per log decrease; P = 0.001). Spot urinary creatinine was associated with Evans criteria of cachexia (OR = 1.26 per log decrease, 95% CI = 1.04–1.49; P = 0.016) and clustered with markers of heart failure severity in hierarchical cluster analyses. Lower urinary creatinine was associated with poorer exercise capacity and quality of life (both P < 0.001) and predicted a higher rate for all-cause mortality [hazard ratio (HR) = 1.27, 95% CI = 1.17–1.38 per log decrease; P < 0.001] and the combined endpoints HF hospitalization or all-cause mortality (HR = 1.23, 95% CI = 1.15–1.31 per log decrease; P < 0.001). Significance was lost after addition of the BIOSTAT risk model. Analyses of the validation cohort yielded similar findings. Conclusions Lower spot urinary creatinine is associated with smaller body dimensions, renal dysfunction, and more severe HF in patients with new-onset/WHF. Additionally, lower spot urinary creatinine is associated with an increased risk of weight loss and a poorer exercise capacity/quality of life. Urinary creatinine could therefore be a novel, easily obtainable marker to assess (risk of) muscle wasting in HF patients.en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleThe value of spot urinary creatinine as a marker of muscle wasting in patients with new-onset or worsening heart failureen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1002/jcsm.12690
dc.identifier.cristin1979364
dc.source.journalJournal of Cachexia, Sarcopenia and Muscleen_US
dc.source.pagenumber555-567en_US
dc.identifier.citationJournal of Cachexia, Sarcopenia and Muscle. 2021, 12 (3), 555-567.en_US
dc.source.volume12en_US
dc.source.issue3en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal